Norlase to continue investments: New product and production expansion in the pipeline

Although Norlase spent 2022 investing in new production facilities, the medical device company is not done on that front. Significant new investments lie ahead, says CEO Oliver Hvidt. 
Photo: Gregers Tycho/Ritzau Scanpix
Photo: Gregers Tycho/Ritzau Scanpix

According to CEO Oliver Hvidt, the financial year 2022 was another year characterized by major investments for medical company Norlase, which develops laser solutions for the treatment of eye diseases. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading